Speech Pathology Telepractice Beneficial in Head, Neck Cancer

This article originally appeared here.
Share this content:
Speech Pathology Telepractice Beneficial in Head, Neck Cancer
Speech Pathology Telepractice Beneficial in Head, Neck Cancer

FRIDAY, March 3, 2017 (HealthDay News) -- For patients with head and neck cancer, a multisite speech pathology telepractice service is associated with higher service efficiency and treatment satisfaction compared with standard care, according to a study published online Feb. 22 in Head & Neck.

Clare L. Burns, Ph.D., from Royal Brisbane and Women's Hospital in Australia, and colleagues conducted a multicenter controlled trial within a large public cancer service. Referrals from speech pathologists at three regional sites were managed by a specialist clinician from a cancer center via standard care, which comprised phone, e-mail support, and appointments at the cancer center, or via a newly established telepractice service, which included online consultation between the cancer center and the regional sites. Data were included for 82 referrals that were managed: 39 for standard care and 43 for telepractice care.

The researchers found that service efficiency favored the telepractice model, with a significant decrease in the number and duration of contact events needed for referral management (P = 0.004 and P = 0.024, respectively). The telepractice service also had higher consumer and clinician satisfaction.

"A speech pathology telepractice service benefits both the patient and health provider through higher service efficiency and treatment satisfaction," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »